Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Does Cannabis Interact with Dementia Medications? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As research into medical cannabis expands, one emerging concern is whether THC or CBD may interact with medications commonly used to treat dementia. Drugs such as donepezil, rivastigmine, galantamine, and memantine rely on specific liver enzymes for metabolism. Because cannabinoids can affect these same pathways, combining them may alter drug levels or increase side effects such as sedation, confusion, or low blood pressure. 

Can medical cannabis be accessed legally for women’s health?

How Cannabis Interacts with Dementia Drugs 

Cannabis compounds are processed in the liver through cytochrome P450 (CYP450) enzymes. 

  • CBD is a strong inhibitor of CYP3A4 and CYP2C19, enzymes responsible for metabolising many dementia and psychiatric medications. This may increase blood levels of donepezil, galantamine, or antidepressants such as sertraline and citalopram (Pharmaceutics, 2024). 
  • THC also uses CYP2C9 and CYP3A4, potentially affecting the metabolism of memantine and certain antipsychotics. 

A review in Frontiers in Psychiatry (2023) found that cannabinoids can change drug exposure by 25% or more when combined with CYP-metabolised medicines, a clinically relevant difference for older adults on multiple prescriptions. 

What The Research Shows 

Older adults in dementia trials using THC: CBD oils often reported mild sedation or dizziness, especially during dose titration. A 2024 Age and Ageing meta-analysis (Age and Ageing, 2024) confirmed that THC-containing products increase fatigue and motor instability, while CBD-only formulations cause minimal side effects. Because both compounds can lower blood pressure, additive effects may occur when combined with cholinesterase inhibitors, which already carry a risk of bradycardia or fainting. 

NICE, NHS, And Alzheimer’s Society Guidance 

  • NICE NG97 does not recommend cannabinoids for dementia, warning of sedation and hypotension in frail patients. 
  • NICE NG144 limits cannabis-based prescriptions to specific conditions and highlights somnolence as a frequent side effect. 
  • The NHS advises that cannabis can slow reactions and cause drowsiness, affecting medication management. 
  • The Alzheimer’s Society UK emphasises that while some studies explore cannabinoid benefits, supervision is essential due to possible confusion and balance issues. 

Clinical Bottom Line 

  • CBD may raise levels of cholinesterase inhibitors and antidepressants by slowing liver metabolism. 
  • THC can add to sedation, dizziness, or low blood pressure. 
  • Polypharmacy and frailty heighten the risks of drug interactions. 
  • NICE and NHS recommend prescribing cannabinoids only under specialist oversight. 

Educational Context: AlleviMed 

AlleviMed provides public education about medical cannabis regulation in the UK. It explains how products are prescribed under MHRA and Home Office frameworks but clarifies that cannabis is not licensed for dementia and requires specialist supervision to avoid drug interactions. 

Takeaway 

Cannabis compounds can interfere with how dementia medicines are broken down in the body. THC may increase sedation and confusion, while CBD can alter drug levels through liver enzyme inhibition. According to NHS, NICE, and Alzheimer’s Society UK, combining cannabis with dementia treatments should only occur under expert medical guidance to ensure safety and minimise adverse effects. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories